Diabetes Care:血清载脂蛋白与2型糖尿病的前瞻性队列研究

2016-12-30 MedSci MedSci原创

近期,一项发表在Diabetes Care杂志上的研究系统性评估了各种载脂蛋白的血清水平在2型糖尿病(T2D)疾病风险中的作用。研究共收集了971名受试者的各种检测数据。研究者们研究了HDL胆固醇(HDL-C)、apoA1、apoCIII、apoD、apoE以及apoA1载脂蛋白的比例与T2D风险的相关性。通过自然对数转化使所有载脂蛋白、比率值和HDL-C的水平达到正态分布。首先,通过使用线性回归

近期,一项发表在Diabetes Care杂志上的研究系统性评估了各种载脂蛋白的血清水平在2型糖尿病(T2D)疾病风险中的作用。

研究共收集了971名受试者的各种检测数据。研究者们研究了HDL胆固醇(HDL-C)、apoA1、apoCIII、apoD、apoE以及apoA1载脂蛋白的比例与T2D风险的相关性。

通过自然对数转化使所有载脂蛋白、比率值和HDL-C的水平达到正态分布。首先,通过使用线性回归来研究它们与空腹葡萄糖和胰岛素的相关性。其次,使用Cox比例风险模型来检查载脂蛋白是否能够预测在基线时在没有糖尿病的个体中发展至T2D的风险。

此项研究经过13.5年随访后(中位随访时间),110名受试者发展为糖尿病。在校正年龄、性别、BMI、糖尿病史、高血压、饮酒、吸烟、心血管疾病和降血脂因素后,HDL-C(每1 SD自然对数转换风险比0.74 [95%CI 0.57,0.97],apoCIII(1.65 [1.42,1.91]),apoE(1.36 [1.18,1.55]),apoCIII与apoA1比率(1.72 [1.51,1.95]),apoE与apoA1比率(1.28 [ ,1.45])和载脂蛋白评分(1.60 [1.39,1.83])与T2D发生仍然显着相关。但是,校正甘油三酯因素后,只有apoCIII(1.42 [1.03,1.96])和apoCIII与apoA1比(1.56 [1.04,2.36]仍然与T2D发生相关。

此项研究表明:血清apoCIII水平以及apoCIII与apoA1比率与T2D发生相关,它们与T2D的相关性与已知的风险因子无关并且比HDL-C水平与T2D的相关性更强。

原始出处:
Brahimaj A, Ligthart S, Ikram MA, Hofman A, Franco OH, Sijbrands EJ, Kavousi M, Dehghan A. Serum Levels of Apolipoproteins and Incident Type 2 Diabetes: A Prospective Cohort Study. Diabetes Care. 2016 Dec 28. pii: dc161295. doi: 10.2337/dc16-1295.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2006371, encodeId=81b120063e188, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat Apr 29 10:33:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637570, encodeId=49a6163e570d0, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jan 01 15:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759837, encodeId=55471e5983789, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Nov 14 23:33:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954309, encodeId=729a195430982, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jul 17 05:33:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937614, encodeId=e1a1193e61441, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sun Aug 06 14:33:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901521, encodeId=2cac190152149, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Nov 10 02:33:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361282, encodeId=990b13612822a, content=<a href='/topic/show?id=2c509364ea9' target=_blank style='color:#2F92EE;'>#载脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93647, encryptionId=2c509364ea9, topicName=载脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sun Jan 01 07:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424658, encodeId=f84414246582e, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Sun Jan 01 07:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167017, encodeId=ba5d16e017b4, content=继续学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Dec 31 11:44:07 CST 2016, time=2016-12-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2006371, encodeId=81b120063e188, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat Apr 29 10:33:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637570, encodeId=49a6163e570d0, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jan 01 15:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759837, encodeId=55471e5983789, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Nov 14 23:33:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954309, encodeId=729a195430982, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jul 17 05:33:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937614, encodeId=e1a1193e61441, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sun Aug 06 14:33:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901521, encodeId=2cac190152149, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Nov 10 02:33:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361282, encodeId=990b13612822a, content=<a href='/topic/show?id=2c509364ea9' target=_blank style='color:#2F92EE;'>#载脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93647, encryptionId=2c509364ea9, topicName=载脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sun Jan 01 07:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424658, encodeId=f84414246582e, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Sun Jan 01 07:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167017, encodeId=ba5d16e017b4, content=继续学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Dec 31 11:44:07 CST 2016, time=2016-12-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2006371, encodeId=81b120063e188, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat Apr 29 10:33:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637570, encodeId=49a6163e570d0, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jan 01 15:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759837, encodeId=55471e5983789, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Nov 14 23:33:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954309, encodeId=729a195430982, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jul 17 05:33:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937614, encodeId=e1a1193e61441, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sun Aug 06 14:33:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901521, encodeId=2cac190152149, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Nov 10 02:33:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361282, encodeId=990b13612822a, content=<a href='/topic/show?id=2c509364ea9' target=_blank style='color:#2F92EE;'>#载脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93647, encryptionId=2c509364ea9, topicName=载脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sun Jan 01 07:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424658, encodeId=f84414246582e, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Sun Jan 01 07:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167017, encodeId=ba5d16e017b4, content=继续学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Dec 31 11:44:07 CST 2016, time=2016-12-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2006371, encodeId=81b120063e188, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat Apr 29 10:33:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637570, encodeId=49a6163e570d0, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jan 01 15:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759837, encodeId=55471e5983789, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Nov 14 23:33:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954309, encodeId=729a195430982, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jul 17 05:33:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937614, encodeId=e1a1193e61441, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sun Aug 06 14:33:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901521, encodeId=2cac190152149, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Nov 10 02:33:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361282, encodeId=990b13612822a, content=<a href='/topic/show?id=2c509364ea9' target=_blank style='color:#2F92EE;'>#载脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93647, encryptionId=2c509364ea9, topicName=载脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sun Jan 01 07:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424658, encodeId=f84414246582e, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Sun Jan 01 07:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167017, encodeId=ba5d16e017b4, content=继续学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Dec 31 11:44:07 CST 2016, time=2016-12-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2006371, encodeId=81b120063e188, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat Apr 29 10:33:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637570, encodeId=49a6163e570d0, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jan 01 15:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759837, encodeId=55471e5983789, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Nov 14 23:33:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954309, encodeId=729a195430982, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jul 17 05:33:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937614, encodeId=e1a1193e61441, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sun Aug 06 14:33:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901521, encodeId=2cac190152149, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Nov 10 02:33:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361282, encodeId=990b13612822a, content=<a href='/topic/show?id=2c509364ea9' target=_blank style='color:#2F92EE;'>#载脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93647, encryptionId=2c509364ea9, topicName=载脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sun Jan 01 07:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424658, encodeId=f84414246582e, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Sun Jan 01 07:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167017, encodeId=ba5d16e017b4, content=继续学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Dec 31 11:44:07 CST 2016, time=2016-12-31, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2006371, encodeId=81b120063e188, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat Apr 29 10:33:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637570, encodeId=49a6163e570d0, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jan 01 15:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759837, encodeId=55471e5983789, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Nov 14 23:33:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954309, encodeId=729a195430982, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jul 17 05:33:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937614, encodeId=e1a1193e61441, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sun Aug 06 14:33:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901521, encodeId=2cac190152149, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Nov 10 02:33:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361282, encodeId=990b13612822a, content=<a href='/topic/show?id=2c509364ea9' target=_blank style='color:#2F92EE;'>#载脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93647, encryptionId=2c509364ea9, topicName=载脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sun Jan 01 07:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424658, encodeId=f84414246582e, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Sun Jan 01 07:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167017, encodeId=ba5d16e017b4, content=继续学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Dec 31 11:44:07 CST 2016, time=2016-12-31, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2006371, encodeId=81b120063e188, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat Apr 29 10:33:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637570, encodeId=49a6163e570d0, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jan 01 15:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759837, encodeId=55471e5983789, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Nov 14 23:33:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954309, encodeId=729a195430982, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jul 17 05:33:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937614, encodeId=e1a1193e61441, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sun Aug 06 14:33:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901521, encodeId=2cac190152149, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Nov 10 02:33:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361282, encodeId=990b13612822a, content=<a href='/topic/show?id=2c509364ea9' target=_blank style='color:#2F92EE;'>#载脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93647, encryptionId=2c509364ea9, topicName=载脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sun Jan 01 07:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424658, encodeId=f84414246582e, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Sun Jan 01 07:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167017, encodeId=ba5d16e017b4, content=继续学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Dec 31 11:44:07 CST 2016, time=2016-12-31, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2006371, encodeId=81b120063e188, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat Apr 29 10:33:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637570, encodeId=49a6163e570d0, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jan 01 15:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759837, encodeId=55471e5983789, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Nov 14 23:33:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954309, encodeId=729a195430982, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jul 17 05:33:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937614, encodeId=e1a1193e61441, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sun Aug 06 14:33:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901521, encodeId=2cac190152149, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Nov 10 02:33:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361282, encodeId=990b13612822a, content=<a href='/topic/show?id=2c509364ea9' target=_blank style='color:#2F92EE;'>#载脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93647, encryptionId=2c509364ea9, topicName=载脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sun Jan 01 07:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424658, encodeId=f84414246582e, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Sun Jan 01 07:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167017, encodeId=ba5d16e017b4, content=继续学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Dec 31 11:44:07 CST 2016, time=2016-12-31, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=2006371, encodeId=81b120063e188, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat Apr 29 10:33:00 CST 2017, time=2017-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637570, encodeId=49a6163e570d0, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Jan 01 15:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759837, encodeId=55471e5983789, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Nov 14 23:33:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954309, encodeId=729a195430982, content=<a href='/topic/show?id=d35532648cb' target=_blank style='color:#2F92EE;'>#前瞻性队列研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32648, encryptionId=d35532648cb, topicName=前瞻性队列研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jul 17 05:33:00 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937614, encodeId=e1a1193e61441, content=<a href='/topic/show?id=f2e83264edb' target=_blank style='color:#2F92EE;'>#前瞻性队列#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32647, encryptionId=f2e83264edb, topicName=前瞻性队列)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Sun Aug 06 14:33:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901521, encodeId=2cac190152149, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Nov 10 02:33:00 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361282, encodeId=990b13612822a, content=<a href='/topic/show?id=2c509364ea9' target=_blank style='color:#2F92EE;'>#载脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93647, encryptionId=2c509364ea9, topicName=载脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sun Jan 01 07:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424658, encodeId=f84414246582e, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Sun Jan 01 07:33:00 CST 2017, time=2017-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=167017, encodeId=ba5d16e017b4, content=继续学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Dec 31 11:44:07 CST 2016, time=2016-12-31, status=1, ipAttribution=)]
    2016-12-31 往日如昨

    继续学习中

    0

相关资讯

陆国平:选择更为适合中国人群的降脂策略——《中国成人血脂异常防治指南(2016年修订版)》要点解读

《中国成人血脂异常防治指南(2016年修订版)》(以下简称指南)已于2016年10月24日发布,该版指南距上版已九年有余,自修订起便受到持续关注。新版指南在2007年版《中国成人血脂异常防治指南》的基础上更新,对LDL-C靶目标值、危险分层标准、干预靶目标等方面均作了强调或改变。在指南修订的过程中专家组有哪些思维的碰撞?针对核心问题讨论时又擦出了怎样的火花?《门诊》特别邀请新版指南修订委员会专

王拥军教授:我国新版血脂指南的可取之处,明确了缺血性卒中他汀治疗的长期应用

2007年,由多学科专家组成的联合委员会制定《中国成人血脂异常防治指南》对我国的血脂异常及相关疾病的防治起到重要的指导作用。翘首九年,《中国成人血脂异常防治指南(2016修订版)》终在10月24日正式发布。九年间,大量新的循证医学证据不断涌现,国内外指南相继发布。依托循证证据,借鉴欧美血脂相关指南,以及参考我国疾病谱的改变,来自国家心血管病中心,中华医学会心血管病学分会、中华医学会糖尿病学分会、中

Diabetes Care:HbA1c水平和BMI对1型糖尿病的血脂有什么影响?

探讨1型糖尿病患者从青少年时期进入到成年早期,糖化血红蛋白(HbA1c)和体重指数(BMI,测量值为BMI z评分[zBMI])对低密度脂蛋白(LDL)、高密度脂蛋白(HDL)和非HDL轨迹的影响。研究纳入572名青年1型糖尿病患者进行动态额回顾性队列研究,调查血脂值的变化,纵向的中位数时间为9.3年。通过纵向建模,我们描述HbA1c和zBMI与血脂值的关系,并且校正了其他相关因素,包括降脂药物的

AM J MED:芝麻油和稻米油混合可控制血糖和血脂

芝麻油富含不饱和脂肪酸,在食用油中,利用不饱和脂肪酸代替饱和脂肪酸有助于预防和治疗糖尿病。稻米油富含谷维素、生育酚和生育三烯酚等健康成分,其中的γ-谷维素已经被证明具有降胆固醇和抗氧化的作用。那么问题来了,如果将两者混合作为烹饪油食用,对2型糖尿病患者的血糖和血脂有何影响?日本福冈大学与丰益国际、印度医学研究委员会合作,针对300名2型糖尿病患者和100名健康受试者,进行了为期8周的开放标签随机试

新血脂指南:走中国路 穿中国鞋(2016年修订版)

10月24日,《中国成人血脂异常防治指南(2016年修订版)》重磅发布,新指南距2007年发布的上一版指南已接近十年。新指南有哪些更新变化?哪些关键要点值得关注?本期,特为读者奉上指南撰写专家和心血管领域专家的权威解读。 集本土化、权威性、公益性、科学性于一身▲北京大学人民医院心脏中心  胡大一近十年来,血脂领域国际国内的研究和观点发生了巨大变化,血脂指南的更新势在必行。从

血脂高?怎么调?送你“三大法宝”

导语:很多人都是噢在体检时意外发现高血脂,高血脂症是血脂代谢异常的表现,由于血脂升高本身并不引起症状,很多人未能在哦公司起来。这相当于给自己的身体埋下了一颗“定时炸弹”,过多的脂质会逐渐沉淀在血管壁,引起血管硬化甚至堵塞,引发严重的心血管疾病。